AFT Pharmaceuticals welcomed the Australian Federal Court’s decision this week to allow its appeal of a comparative advertising judgement brought by Reckitt Benckiser.
The Australian Federal Court has found AFT was justified in making a series of claims in relation to the efficacy of its Maxigesic pain relief tablets in comparison to Ibuprofen alone or paracetamol alone.
Reckitt Benckiser has until 4 January 2022 to file an application for special leave to appeal to the High Court should it so chose.
